Semax
ContestedNootropic Peptide
Our read of public sources: some pharmacies compound it under a legal theory — a differentiated-formulation argument, or in anticipation of a pending committee recommendation — that no court ruling or final FDA rule has settled either way. We're flagging this as actively debated, not as a green or red light. This is not a legal determination; verify independently before relying on it.
Not legal advice. Every status on this page is our own reading of public FDA guidance, shortage listings, and committee materials — it has not been reviewed by an attorney and is not a legal determination. "Contested" means pharmacies and regulators publicly disagree, not that we're resolving the disagreement. Verify independently, and check with counsel, before relying on any entry here.
Current status
Not currently on the permitted 503A bulk substances list. Included in the July 23–24, 2026 PCAC 8–6 (1 abstain) vote recommending addition to the bulks list; FDA staff opposed, citing insufficient characterization data and no USP monograph, same as the other five peptides in that vote. Remains outside the permitted list pending final FDA action.
Last changed: 2026-07-24